📰 Program Updates News
Page 8 - Program Updates News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Program Updates. Real-time updates on events, politics, business and more.
May 16, 2024
Condensed consolidated income statement Three months ended ...
May 6, 2024
FDA grants Priority Review for sNDA to convert FILSPARI® from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024 Received 511...
April 4, 2024
How Lesley University Descended Into Crisis | News | The Harvard Crimson
March 28, 2024
AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer...
March 11, 2024
Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into 2027 Reports frataxin protein expression data...
February 29, 2024
The Fry Times - HHS Funnel Survivors
February 27, 2024
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 -- Denali Therapeutics Inc. , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier ...
February 16, 2024
The Mine Safety & Health Administration (“MSHA”) has finally published its final rule on Safety Programs for Surface Mobile Equipment. This final rule has been a long time coming....
February 15, 2024
15.02.2024 - Received 459 new patient start forms (PSFs) for FILSPARI (sparsentan) in Q4 2023; Total of 1,452 PSFs received in 2023 Company nearing submission of sNDA to convert U.S. accelerated approval of FILSPARI in IgAN to full approval ...
February 15, 2024
15.02.2024 - First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 Highly selective oral SMARCA2 degrader PRT7732 IND expected to be filed in first half and enter Phase 1 ...